SCHEMBL2072641

SCHEMBL2072641

CCNc1nc2c(c(-c3c(C)cc(C)cc3C)cn2C)c(=O)n1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 12/20 0.66
MAPT P10636 1/20 0.34
LMNA P02545 3/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
MEN1 O00255 2/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CASP1 P29466 2/20 0.34
CASP7 P55210 2/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GLA P06280 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
NR2F2 P24468 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072342 0.85 CRHR1 (0.57) CRHR1LMNAKMT2AHTTSMN1; SMN2
SCHEMBL2070099 0.85 CRHR1 (0.62) CRHR1MAPK1ALDH1A1
SCHEMBL2073108 0.83 CRHR1 (0.63) CRHR1MAPK1ALDH1A1CYP2C9
SCHEMBL2071132 0.83 CRHR1 (0.61) CRHR1MAPK1ALDH1A1
SCHEMBL2071039 0.82 CRHR1 (0.54) CRHR1MAPTLMNATSHRMEN1
SCHEMBL2070092 0.82 CRHR1 (0.60) CRHR1MAPK1ALDH1A1HSD17B10
SCHEMBL2072390 0.81 CRHR1 (0.59) CRHR1MAPK1ALDH1A1
SCHEMBL2071464 0.81 CRHR1 (0.53) CRHR1MAPTLMNATSHRMAPK1
SCHEMBL2072415 0.81 CRHR1 (0.55) CRHR1LMNATSHRMAPK1HTT
SCHEMBL2072033 0.80 CRHR1 (0.52) CRHR1MAPTTSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R CRHR1 1/4885MAPT 4701/4885LMNA 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.